Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Perusing Breakthroughs in Breast Cancer in Pasadena

July 31st 2019

We traveled to Pasadena, California, for a State of the Science Summit™ on Breast Cancer, which featured insights from the faculty from City of Hope.

Precision Medicine Advances in HR+/HER2- Breast Cancer

July 30th 2019

Jane Meisel, MD, provides insight on how genomic assays are helping to individualize treatment plans and strategies to determine the optimal duration of endocrine therapy.

Abemaciclib/Fulvestrant Combo Improves OS in HR+ Advanced Breast Cancer

July 30th 2019

Abemaciclib plus fulvestrant improved overall survival in patients with hormone receptor–positive, HER2-negative breast cancer.

Pembrolizumab Combo Improves pCR in Locally Advanced TNBC

July 29th 2019

Pembrolizumab in combination with chemotherapy led to a statistically significant improvement in pathological complete response rates compared with placebo plus chemotherapy in the neoadjuvant phase of a neoadjuvant/adjuvant treatment regimen in patients with triple-negative breast cancer, meeting one of the dual primary endpoints of the phase III KEYNOTE-522 trial.

How CDK4/6 Inhibitors Are Shaking Up the Breast Cancer Paradigm

July 28th 2019

During a recent OncLive Peer Exchange®, a panel of breast cancer experts discussed how they are using CDK4/6 inhibitors in their practices. They shared their insights on the tolerability and toxicity profiles of the FDA-approved CDK4/6 inhibitors, how they choose which agents to use for each patient, and how they select the next line of therapy after the patient progresses.

Final Thoughts on the Treatment of Breast Cancer

July 16th 2019

Genomic/Somatic Molecular Alteration Evaluation

July 16th 2019

Treatment of Germline BRCA with PARP and Checkpoint

July 16th 2019

The Use of Chemotherapy and Checkpoint Inhibitors for TNBC

July 16th 2019

Immunotherapy for Triple-Negative Breast Cancer

July 16th 2019

Approach to Neoadjuvant Therapy for Triple-Negative Breast Cancer

July 16th 2019

Emerging Agents for Relapsed-Refractory HER2+ MBC

July 16th 2019

Treatment Options for Metastatic HER2+ Breast Cancer

July 16th 2019

Treatment of Homogeneous Tumors vs Heterogenetic Tumors

July 16th 2019

Trials That Shaped HER2-Positive Therapy for BC

July 16th 2019

TAILORx Trial for ER-Positive Patients

July 16th 2019

Implications of Finding Patients With PIK3CA Mutations

July 16th 2019

Treatment After Progression on CDK4/6

July 16th 2019

Predictive and Prognostic Biomarkers and Resistance Mutations

July 16th 2019

MONALEESA-2 and Choosing Among the CDK4/6

July 16th 2019